Navigation Links
Study Points to New Treatments for Polycystic Kidney Disease
Date:4/11/2008

Molecules called CFTR inhibitors show promise in slowing growth of masses

FRIDAY, April 11 (HealthDay News) -- Compounds called CFTR inhibitors show promise in slowing the progression of polycystic kidney disease (PKD), according to preliminary research conducted at the University of California, San Francisco, School of Medicine.

PKD is the most common kind of genetic kidney disease. Patients develop cysts on the kidneys, which progressively increase in size and number. As a result, the kidneys become enlarged, eventually leading to kidney failure. There is no cure for PKD.

It's believed the accumulation of fluid in the cysts is related to chloride secretion, which is affected by the CFTR (cystic fibrosis transmembrane conductance regulator) gene, according to background information in a news release about the research.

"The CFTR inhibitors could be the basis of a lifelong treatment to slow renal cyst growth and decline in renal function, prolonging dialysis-free patient survival," researcher Dr. Alan S. Verkman said in a prepared statement.

In laboratory tests, he identified a few CFTR inhibitors that reduced the number and growth of cysts by more than 80 percent. He then tested these inhibitors in mice genetically engineered to develop a condition similar to PKD.

Mice treated with these CFTR inhibitors for up to seven days had significantly slower cyst expansion and kidney enlargement, and better preservation of kidney function. There was no evidence that the CFTR inhibitors harmed kidney function.

The findings indicate that CFTR plays a role in the growth of kidney cysts and suggest that CFTR inhibitors may prove useful in treating PKD. However, much more research needs to be done, Verkman said.

"The mouse model of PKD is not the real human disease for many reasons, such as the more rapid progression of disease in mice. Clinical trials will be needed to determine the efficacy of these compounds in human PKD," he said.

The research was expected to be published in the July issue of the Journal of the American Society of Nephrology.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about PKD.



-- Robert Preidt



SOURCE: American Society of Nephrology, news release, April 2, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. MRI better than MDCT in detecting endoleaks, study says
2. Personality study shows risk of first depression episode late in life
3. 3T MRI plays significant role in detecting prostate cancer, study says
4. Study shows doctors offices can help stem abuse of Oxycontin, other narcotic painkillers
5. Quintiles Ranks First in Pan-European Clinical Investigator Study
6. Study Showed Minimally Invasive Surgery Reduced Risk of Hospital-Acquired Infections Compared to Open Surgery
7. NEJM study demonstrates carotid stenting with embolic protection is comparable to surgery
8. Egg Consumption Poses Risks for Diabetic Men: Study
9. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
10. Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide
11. Forecasting MDs prescriptions choice? Ask their patients, says Management Insights study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 ... ... Company, Cal Dining at the University of California Berkeley, and other leading institutions ... leverages the buying power of institutions to change the way animals are raised ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: